Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ultra-low-dose radiotherapy combined with zuberitamab for limited-stage MALT lymphoma
ChiCTR2600134003Phase 2Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Jul 2026
- Modality
- IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of hlx01 in extranodal marginal zone B-cell lymphoma (EMZL) and Gastric Marginal Zone B-Cell Lymphoma Of Mucosa-Associated Lymphoid Tissue, sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Complete response rate at 6 months after completion of the combined treatment. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
hlx01
03
Conditions
extranodal marginal zone B-cell lymphoma (EMZL)Gastric Marginal Zone B-Cell Lymphoma Of Mucosa-Associated Lymphoid Tissue
Beyond the preview
Go deeper on ChiCTR2600134003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600134003.